Targeting RAS in neuroblastoma: Is it possible?

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neuroblastoma is a common childhood cancer with complex pathogenesis.
• Genetic heterogeneity limits current monotherapy efficacy.
• RAS mutations are increasingly recognized in recurrent neuroblastoma.

Purpose of the Study:

• To review the biological role of RAS in neuroblastoma.
• To summarize the frequency of RAS mutations in neuroblastoma.
• To discuss therapeutic strategies targeting RAS mutations in neuroblastoma.

Main Methods:

• Literature review of studies on RAS mutations in neuroblastoma.
• Analysis of preclinical and clinical data for RAS-targeted therapies.
• Exploration of the MAPK pathway's role in RAS-driven neuroblastoma.

Main Results:

• RAS mutations activate the MAPK pathway, crucial for neuroblastoma development.
• Targeting RAS mutations shows promise in preclinical models.
• Existing therapies for RAS-mutated tumors offer insights for neuroblastoma treatment.

Conclusions:

• RAS mutations represent a significant therapeutic target in neuroblastoma.
• Personalized therapies targeting RAS are essential for improving outcomes.
• Further research and clinical trials are needed to overcome challenges in treating RAS-mutated neuroblastoma.